Novo-Nordisk, a pharmaceutical company, does user research with patients to enhance understanding of patients and to develop products that meet users’ needs.
Patients Involved Case Report
Involvement of the foundation ‘Children with SMA’ (spinal muscular atrophy) with an academic institution in Ukraine to design a pilot clinical trial addressing issues in SMA clinical trials.
Involvement of European Tuberous Sclerosis Complex Patient Organisations (E-TSC) establishing an European registry of patients living with Tuberous sclerosis complex (TSC) to address some gaps in understanding the clinical course of TSC and the therapeutic outcomes.
Novartis Advisory Board meets with six National Psoriasis Patient Organisations to address patient relevant endpoints in psoriasis clinical trials.
Collaboration between patients and a Psoriasis Association representative with the ‘Focus on the Patient’ division from GSK, to understand the impact of psoriasis on the lives of patients, their own views, and future clinical study endpoints.
Patients were asked by GlaxoSmithKline staff members to review a draft plain language summary from a completed Phase III study. The patients provided valuable feedback about the wording, structure, and content of the plain language summary.
Collaboration between the International Alliance of Patient’s Organisations and local patient organisations with pharmaceutical company Novo Nordisk A/S to facilitate dialogue between them and develop learnings for future use.
Medical anthropologists and patients gain insights into what is living with sickle cell disease.
It is important to have information reachable for patient’s organisations, so they can publish it using their tools and making it more accessible for patients.
Collaboration between patient advocates with academic institutions (Northwestern University and Emory University) and a pharmaceutical company Merck (Health Literacy and Healthcare Disparities Strategy group) to obtain a simplified label with a format that nearly everyone can understand, including vulnerable groups.